Dovitinib: Rationale, preclinical and early clinical data in urothelial carcinoma of the bladder

Expert Opinion on Investigational Drugs

Volumn 23, Issue 11, 2014, Pages 1553-1562

  Mazzola, Clarisse R ^a   Siddiqui, Khurram M ^a   Billia, Michele ^a   Chin, Joseph ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bladder cancer; Clinical trial; Dovitinib; Phase I trial; Phase II trial; Preclinical studies; Targeted agents; TKI 258; TKI258; Urothelial carcinoma

Indexed keywords

DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; IMMUNOTOXIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR 2; 4-AMINO-5-FLUORO-3-(5-(4-METHYLPIPERAZIN-1-YL)-1H-BENZIMIDAZOL-2-YL)QUINOLIN-2(1H)-ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; QUINOLONE DERIVATIVE;

ADVANCED CANCER; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CLINICAL STUDY; DRUG TARGETING; EVALUATION STUDY; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; SIGNAL TRANSDUCTION; SOLID TUMOR; TRANSITIONAL CELL CARCINOMA; ANIMAL; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; GENETICS; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; QUINOLONES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 84911887331     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.966900     Document Type: Article

References (94)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9
2. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013;63:234
3. Lehmann J, Retz M, Wiemers C, et al. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 2005;23:4963
4. Parekh DJ, Bochner BH, Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J Clin Oncol 2006;24:5519
5. Chalasani V, Kassouf W, Chin JL, et al. Radical cystectomy for the treatment of T1 bladder cancer: the Canadian bladder cancer network experience. Can Urol Assoc J 2011;5:83
6. Vaidya A, Soloway MS, Hawke C, et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol 2001;165:47
7. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639
8. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014;65:778
9. Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012;39:598
10. Burger M, Oosterlinck W, Konety B, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2013;63:36
11. Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinomaneoadjuvant and adjuvant settings. Eur Urol 2013;63:58
12. Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37:219
13. Lindgren D, Frigyesi A, Gudjonsson S, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463
14. Lindgren D, Sjodahl G, Lauss M, et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One 2012;7:e38863
15. Sjodahl G, Lauss M, Gudjonsson S, et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One 2011;6:e18583
16. Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18:3377
17. Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in highgrade bladder cancer. J Clin Oncol 2013;31:3133
18. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010;3:1
19. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011;43:875
20. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005;4:1
21. Fadl-Elmula I, Gorunova L, Mandahl N, et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000;29:256
22. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552
23. Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, et al. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 2010;28:401
24. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315
25. Gartrell BA, Sonpavde G. Emerging drugs for urothelial carcinoma. Expert Opin Emerg Drugs 2013;18:477
26. Balar AV, Apolo AB, Ostrovnaya I, et al. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. J Clin Oncol 2013;31:724
27. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatinbased chemotherapy: baseline interleukin- 8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22:2646
28. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373
29. Galsky MD, Hahn NM, Powles T, et al. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013;11:175
30. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: hoosier Oncology Group GU 04-75. J Clin Oncol 2011;29:1525
31. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391
32. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 2011;29:1045
33. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4090
34. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinumresistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 2012;13:810
35. Gerullis H, Eimer C, Ecke TH, et al. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after firstline therapy. Anticancer Drugs 2013;24:422
36. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology 2010;76:923
37. Choueiri TK, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinumpretreated metastatic urothelial cancer. J Clin Oncol 2012;30:507
38. Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int 2010;105:317
39. Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol 2009;20:1074
40. Pruthi RS, Nielsen M, Heathcote S, et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int 2010;106:349
41. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol 2012;30:3545
42. Galsky MD, Von Hoff DD, Neubauer M, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012;30:695
43. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218
44. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, openlabel phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009;115:2881
45. Milowsky MI, Iyer G, Regazzi AM, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112:462
46. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012;23:2663
47. Grivas PD, Hussain M, Hafez K, et al. A phase II trial of neoadjuvant nabpaclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology 2013;82:111
48. Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 2014;120(17):2684-93
49. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol 2013;14:769
50. Thompson LM, Plummer S, Schalling M, et al. A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics 1991;11:1133
51. Perez-Castro AV, Wilson J, Altherr MR. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997;41:10
52. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165
53. Chellaiah A, Yuan W, Chellaiah M, et al. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity. J Biol Chem 1999;274:34785
54. Shimizu A, Tada K, Shukunami C, et al. A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 2001;276:11031
55. Scotet E, Houssaint E. The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific. Biochim Biophys Acta 1995;1264:238
56. Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694
57. Ong SH, Hadari YR, Gotoh N, et al. Stimulation of phosphatidylinositol 3- kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci USA 2001;98:6074
58. Ong SH, Guy GR, Hadari YR, et al. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol 2000;20:979
59. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304:417
60. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265
61. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001;158:1955
62. Iyer G, Milowsky MI. Fibroblast growth factor receptor-3 in urothelial tumorigenesis. Urol Oncol 2013;31:303
63. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18
64. van Oers JM, Wild PJ, Burger M, et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 2007;52:760
65. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912
66. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108
67. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007;26:5889
68. van Rhijn BW, van der Kwast TH, Liu L, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012;187:310
69. Gust KM, McConkey DJ, Awrey S, et al. Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer. Mol Cancer Ther 2013;12:1245
70. Rebouissou S, Herault A, Letouze E, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol 2012;227:315
71. van Oers JM, Zwarthoff EC, Rehman I, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 2009;55:650
72. van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911
73. Mhawech-Fauceglia P, Cheney RT, Fischer G, et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32:231
74. Bernard-Pierrot I, Brams A, Dunois-Larde C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006;27:740
75. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91
76. Gomez-Roman JJ, Saenz P, Molina M, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005;11:459
77. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009;119:1216
78. Gorbenko O, Ovcharenko G, Klymenko T, et al. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3. Hybridoma (Larchmt) 2009;28:295
79. Martinez-Torrecuadrada J, Cifuentes G, Lopez-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human singlechain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005;11:6280
80. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, et al. Antitumor activity of fibroblast growth factor receptor 3- specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 2008;7:862
81. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116
82. Lamont FR, Tomlinson DC, Cooper PA, et al. Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104:75
83. Hanze J, Henrici M, Hegele A, et al. Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer 2013;13:589
84. Tai WT, Cheng AL, Shiau CW, et al. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol Cancer Ther 2012;11:452
85. Hasinoff BB, Wu X, Nitiss JL, et al. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol 2012;84:1617
86. Miyake M, Ishii M, Koyama N, et al. 1- tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2- (4-diethylamino-butylamino)-pyrido[2,3 - d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther 2010;332:795
87. Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{6-[4-(4-ethylpiperazin- 1-yl)-phenylamin o]-pyrimidin- 4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem 2011;54:7066
88. Sarker D, Molife R, Evans TR, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008;14:2075
89. Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res 2013;19:1257
90. Milowsky MI, Dittrich C, Martinez ID, et al. Final results of a multicenter, openlabel phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3. J Clin Oncol 2013;31(Suppl 6):abstract 255
91. US: national Library of Medicine. Clinical Trials.gov (online). Available from: http://clinicaltrials.gov/show/NCT01732107 2013
92. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883
93. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J Clin Invest 2009;119:1077
94. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer - an update. Urol Oncol 2007;25:433